These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36410385)

  • 1. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries.
    Cooper SE; Rosenblatt J; Gulick RM
    Clin Infect Dis; 2022 Nov; 75(Suppl 4):S541-S548. PubMed ID: 36410385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project.
    Nguyen N; Lane B; Golub SA; Chastain C; Zucker J; King K; Terry M; Burdge J; Carnevale C; Muscarella A; Castor D; Kutner B; Meyers K
    J Int AIDS Soc; 2024 Jul; 27 Suppl 1(Suppl 1):e26282. PubMed ID: 38965977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs).
    Kityo C; Cortes CP; Phanuphak N; Grinsztejn B; Venter F
    Clin Infect Dis; 2022 Nov; 75(Suppl 4):S549-S556. PubMed ID: 36410377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States.
    McCrimmon T; Collins LF; Perez-Brumer A; Bazzi AR; Shaffer VA; Kerrigan D; Alcaide ML; Philbin MM
    AIDS Patient Care STDS; 2024 Feb; 38(2):61-69. PubMed ID: 38381949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda.
    Kennedy CE; Zhao T; Vo AV; Nakubulwa R; Nabakka P; Jackson J; Rosen JG; Chang LW; Reynolds SJ; Quinn TC; Nakigozi G; Kigozi G; Kagaayi J; Nalugoda F; Ddaaki WG; Grabowski MK; Nakyanjo N
    AIDS Patient Care STDS; 2023 Jun; 37(6):316-322. PubMed ID: 37294280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus infection challenges: Current therapeutic limitations and strategies for improved management through long-acting injectable formulation.
    Tanushree ; Sharma A; Monika ; Singh RP; Jhawat V
    Rev Med Virol; 2024 Jul; 34(4):e2563. PubMed ID: 38886179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series.
    Kilcrease C; Yusuf H; Park J; Powell A; Rn LJ; Rn JO; Lmsw BD; Weld ED; Dooley KE; Arrington-Sanders R; Agwu AL
    AIDS Res Ther; 2022 Nov; 19(1):56. PubMed ID: 36435793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review.
    Ariyo OE; Jones CE
    J Clin Virol; 2022 Jan; 146():105032. PubMed ID: 34883407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of cabotegravir for HIV treatment and prevention.
    Canetti D; Spagnuolo V
    Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
    [No Abstract]   [Full Text] [Related]  

  • 10. Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South.
    Collins LF; Corbin-Johnson D; Asrat M; Morton ZP; Dance K; Condra A; Jenkins K; Todd-Turner M; Sumitani J; Smith BL; Armstrong WS; Colasanti JA
    Open Forum Infect Dis; 2022 Sep; 9(9):ofac455. PubMed ID: 36147599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "I Feel Like I Don't Even Have HIV Anymore"-Facilitators, Barriers, and Experience regarding Use of Long-Acting Injectable Antiretroviral Therapy Among Persons with HIV in North Carolina.
    Agarwal H; Huffstetler HE; Lopez C; Go VF; Napravnik S; Farel CE; Rutstein SE
    AIDS Patient Care STDS; 2024 Jul; 38(7):324-329. PubMed ID: 38860413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.
    Philbin MM; Parish C; Bergen S; Kerrigan D; Kinnard EN; Reed SE; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Alcaide ML; Metsch LR
    AIDS Patient Care STDS; 2021 Jan; 35(1):23-30. PubMed ID: 33400587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting antiretrovirals and HIV treatment adherence.
    Nachega JB; Scarsi KK; Gandhi M; Scott RK; Mofenson LM; Archary M; Nachman S; Decloedt E; Geng EH; Wilson L; Rawat A; Mellors JW
    Lancet HIV; 2023 May; 10(5):e332-e342. PubMed ID: 37062293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.
    Gandhi RT; Bedimo R; Hoy JF; Landovitz RJ; Smith DM; Eaton EF; Lehmann C; Springer SA; Sax PE; Thompson MA; Benson CA; Buchbinder SP; Del Rio C; Eron JJ; Günthard HF; Molina JM; Jacobsen DM; Saag MS
    JAMA; 2023 Jan; 329(1):63-84. PubMed ID: 36454551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Long-Acting Agents for the Treatment of HIV Infection.
    Rana AI; Castillo-Mancilla JR; Tashima KT; Landovitz RL
    Drugs; 2020 Apr; 80(6):535-545. PubMed ID: 32180205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic.
    Christopoulos KA; Grochowski J; Mayorga-Munoz F; Hickey MD; Imbert E; Szumowski JD; Dilworth S; Oskarsson J; Shiels M; Havlir D; Gandhi M
    Clin Infect Dis; 2023 Feb; 76(3):e645-e651. PubMed ID: 35913500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
    Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
    Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start.
    Pinto RM; Hall E; Tomlin R
    J Assoc Nurses AIDS Care; 2023 Mar-Apr 01; 34(2):216-220. PubMed ID: 36662654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implementation of long-acting antiretroviral treatment in high-income countries: challenges and advantages.
    Waters L; Sparrowhawk A
    Curr Opin HIV AIDS; 2022 May; 17(3):121-126. PubMed ID: 35439786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?
    Scarsi KK; Swindells S
    J Int Assoc Provid AIDS Care; 2021; 20():23259582211009011. PubMed ID: 33902356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.